18,000+ products cover the ten top research categories, including cancer, metabolism, cardiovascular, neuroscience, and stem cells. Each antibody is crafted with care according to rigorous protocols for immunogen design and preparation, presentation to host animal, and high-affinity purification against the antigen. Quality is embedded in the production process to assure the best antibody for you.
Crown antibodies pass additional stringent quality requirements, including extended control sets, uniform results against multiple biologically relevant cell lines and tissues, and function in multiple applications.
Abgent develops 1000+ new products per year. We provide tools for path-breaking research by developing antibodies that detect a comprehensive library of novel and established targets. For established targets we seek to add antibodies that recognize new epitopes, including post-translational modifications such as phosphorylation and methylation. For new targets we consult with leading experts to accelerate development of antibodies that will propel state-of-the-art research in cellular health and disease.
Individual peptides for SARS-CoV-2 Spike glycoprotein. In order to study the specificity of cellular immune responses against SARS CoV-2 and potential immunity caused by other human Corona Viruses, Abcepta provides Spike peptide individually, as pools and in plate. These peptides can be used for antigen specific T-cell stimulation in T-cell assays or T-cell expansion.
All peptides are manufactured in the San Diego, California. Custom peptide services include long peptides (>100 aa), cyclic peptides, difficult sequences, fluorescent labels, phospho-peptides and other post-translational modifications.
The majority of Abcepta antibodies are produced using peptide immunogens. These immuno-specific peptides can be used as blocking agents when using the complementary antibodies in a range of applications.
Abcepta's portfolio of cell lines, tissues and lysates are drawn from a range of species and immortalized cell lines. All our cell lines and lysates are validated in key applications.
These tissue lysates can be used in applications such as SDS-PAGE and Western blotting. Whole cell lysates can be used as positive controls for applications such as ELISAs, immunoprecipitation (IP) and Western blotting.
Obtaining high-quality whole cell lysates can be tedious as well as time consuming. Abcepta offers a comprehensive portfolio of whole cell lysates for research use.
Browse our catalog to find the right whole cell lysate for your experiment.
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
Abcepta is a leading manufacturer of primary antibodies with more than fifteen years of experience. We supply quality antibodies and related products drug discovery and academic laboratories worldwide. Our focus is on targets covering the major research areas impacting health and disease, including cancer, metabolism, cardiovascular, neuroscience, and stem cells.
Founded in 2001, Abcepta is one of the world's largest manufacturers of research user only antibodies. WuXi Apptec, a leading global contract R&D services provider serving the pharmaceutical, biotech, and medical device industries, acquired Abcepta in October of 2011.
With its history as an original manufacturer, Abcepta has a deep and practical understanding of the production process for antibodies, peptides, and recombinant proteins. We have assembled world-class, independently credentialed facilities, operate under a strict project management paradigm with highly trained staff, rigorously test our products in-process and post-production, and monitor customer feedback to assure that we earn the trust of scientists who choose to work with us.
Abcepta may in-licenses select products and technologies to offer our customers a wide variety of options for their proteomic research needs. Contact us for further information and non-disclosure agreements. Our experienced discovery and production teams will work with you to jointly evaluate proposals and identify partnering opportunities.
We believe that attracting and supporting creative and talented people is essential to our success. Abcepta offers an energetic, friendly environment and the opportunity to further scientific research and drug discovery. Abcepta is an Equal Opportunity Employer. Send a cover letter and resume to info@abcepta.com
Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
Store at -20 °C.Stable for 12 months from date of receipt
Protein Information
Name
FZD5
Synonyms
C2orf31
Function
Receptor for Wnt proteins (PubMed:10097073, PubMed:20530549, PubMed:26908622, PubMed:9054360). Functions in the canonical Wnt/beta- catenin signaling pathway. In vitro activates WNT2, WNT10B, WNT5A, but not WNT2B or WNT4 signaling (By similarity). In neurons, activation by WNT7A promotes formation of synapses (PubMed:20530549). May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues (Probable). Plays a role in yolk sac angiogenesis and in placental vascularization (By similarity). Plays a role in ocular development (PubMed:26908622).
Cellular Location
Cell membrane; Multi-pass membrane protein {ECO:0000250|UniProtKB:Q8CHL0}. Golgi apparatus membrane {ECO:0000250|UniProtKB:Q9EQD0}; Multi-pass membrane protein {ECO:0000250|UniProtKB:Q9EQD0}. Synapse {ECO:0000250|UniProtKB:Q8CHL0}. Perikaryon {ECO:0000250|UniProtKB:Q8CHL0}. Cell projection, dendrite {ECO:0000250|UniProtKB:Q8CHL0}. Cell projection, axon {ECO:0000250|UniProtKB:Q8CHL0}. Note=Localized at the plasma membrane and also found at the Golgi apparatus. {ECO:0000250|UniProtKB:Q9EQD0}
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
Submit your citation using an Abcepta antibody to info@abcepta.com, and receive a free "I Love Antibodies" mug.
Citations for related products
Application Protocols
Provided below are standard protocols that you may find useful for product applications.
Receptor for Wnt proteins. Most of frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK- 3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. Interacts specifically with Wnt5A to induce the beta- catenin pathway.
References
Wang Y.,et al.J. Biol. Chem. 271:4468-4476(1996).
Saitoh T.,et al.Int. J. Oncol. 19:105-110(2001).
Hillier L.W.,et al.Nature 434:724-731(2005).
Tanaka S.,et al.Proc. Natl. Acad. Sci. U.S.A. 95:10164-10169(1998).
He X.,et al.Science 275:1652-1654(1997).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.